Apollomics (APLM) Other Non-Current Assets (2021 - 2025)
Apollomics' (APLM) quarterly Other Non-Current Assets came in at $51.3 million in Q4 2025, up 695.21% year-over-year from $6.5 million in Q4 2024, and up 695.21% quarter-over-quarter from $6.5 million in Q4 2024.
Analysis
Apollomics (APLM) Other Non-Current Assets (2021 - 2025) Analysis & Trends
Apollomics (APLM) has reported Other Non-Current Assets for 5 consecutive years, with $51.3 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Other Non-Current Assets rose 695.21% year-over-year to $51.3 million in Q4 2025; TTM through Dec 2025 was $51.3 million, a 695.21% increase from a year earlier, with the FY2025 full-year figure at $51.3 million, up 695.21% from the prior year.
- Other Non-Current Assets was $51.3 million for Q4 2025 at Apollomics, up from $6.5 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $72.5 million in Q4 2021 and troughed at $6.5 million in Q4 2024.
- A 5-year average of $36.7 million and a median of $41.2 million in 2023 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets tumbled 75.53% in 2024 and soared 695.21% in 2025, its largest moves.
- Over 5 years, Other Non-Current Assets stood at $72.5 million in 2021, then slumped by 40.08% to $43.4 million in 2022, then tumbled by 39.29% to $26.4 million in 2023, then plunged by 75.53% to $6.5 million in 2024, then soared by 695.21% to $51.3 million in 2025.
- The last three Other Non-Current Assets figures came in at $51.3 million (Q4 2025), $6.5 million (Q4 2024), and $15.8 million (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - | 51.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 51.32 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Jun 30, 2024 | 15.76 Mn |
| Dec 31, 2023 | 26.37 Mn |
| Jun 30, 2023 | 41.24 Mn |
| Dec 31, 2022 | 43.43 Mn |
| Dec 31, 2021 | 72.48 Mn |